Colin V Gegg

US Patent:

6420339, Jul 16, 2002

Filed:

Oct 14, 1998

Appl. No.:

09/172644

Inventors:

Colin Gegg - Newbury Park CA
Olaf Kinstler - Newbury Park CA

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 3818

US Classification:

514 12, 514 2, 514909, 530350, 530402

Abstract:

The present invention relates generally to the chemical modification of biologically active agents. More, specifically, the invention relates to a novel approach to engineer, through mutagenesis and site-directed chemical conjugation, specific, well-defined dualPEGylated-protein bioconjugates, consisting of two polyethylene glycol (PEG) macromolecules chemically conjugated to the protein at two specifically defined amino acid residues. The described dualPEGylated-protein bioconjugates show substantially improved bioefficacy and biocompatibility.

US Patent:

6420340, Jul 16, 2002

Filed:

Dec 19, 2000

Appl. No.:

09/742601

Inventors:

Colin Gegg - Newbury Park CA
Olaf Kinstler - Newbury Park CA

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 3800

US Classification:

514 12, 514 2, 514 21, 530324, 530350, 5303917, 530402, 530412

Abstract:

The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.

US Patent:

6586398, Jul 1, 2003

Filed:

Apr 7, 2000

Appl. No.:

09/545335

Inventors:

Olaf Kinstler - Newbury Park CA
Colin Gegg - Newbury Park CA
Aimee Freeman - Newbury Park CA
Thomas Boone - Newbury Park CA

Assignee:

Amgen, Inc. - Thousand Oaks CA

International Classification:

A61K 3800

US Classification:

514 12, 514 2, 514 8, 530324, 530350, 530395, 530397, 530399, 530402, 435 694

Abstract:

The present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to novel erythropoietin stimulating protein (NESP).

US Patent:

7442778, Oct 28, 2008

Filed:

Sep 23, 2005

Appl. No.:

11/234731

Inventors:

Colin Gegg - Newbury Park CA, US
Fei Xiong - Thousand Oaks CA, US
Karen C. Sitney - Weston CT, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 16/00
C07H 21/02

US Classification:

5303917, 530350, 5303911

Abstract:

The present invention concerns molecules and a process in which one or more biologically active peptides are incorporated into an Fc domain. In this invention, pharmacologically active compounds may be prepared by a process comprising (a) selecting at least one peptide that modulates the activity of a protein of interest; and (b) preparing a pharmacologic agent comprising an amino acid sequence of the selected peptide in a loop region of an Fc domain. This process may be employed to modify an Fc domain that is already linked through an N- or C-terminus or sidechain to a peptide or to a polypeptide (e. g. , etanercept). This process may also be employed to modify an Fc domain that is part of an antibody (e. g. , adalimumab, epratuzumab, infliximab, Herceptin, and the like). In this way, different molecules can be produced that have additional functionalities, such as a binding domain to a different epitope or an additional binding domain to the precursor molecule's existing epitope.

US Patent:

7645861, Jan 12, 2010

Filed:

Aug 1, 2008

Appl. No.:

12/221414

Inventors:

Colin Gegg - Newbury Park CA, US
Fei Xiong - Thousand Oaks CA, US
Karen C. Sitney - Weston CT, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 16/00
A61K 38/00

US Classification:

5303917, 530350, 5303911

Abstract:

The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.

US Patent:

7655764, Feb 2, 2010

Filed:

Aug 1, 2008

Appl. No.:

12/221412

Inventors:

Colin Gegg - Newbury Park CA, US
Fei Xiong - Thousand Oaks CA, US
Karen C. Sitney - Weston CT, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 16/00
A61K 38/00

US Classification:

5303917, 530350, 5303911

Abstract:

The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.

US Patent:

7655765, Feb 2, 2010

Filed:

Aug 1, 2008

Appl. No.:

12/221421

Inventors:

Colin Gegg - Newbury Park CA, US
Fei Xiong - Thousand Oaks CA, US
Karen C. Sitney - Weston CT, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 16/00
A61K 38/00

US Classification:

5303917, 530350, 5303911

Abstract:

The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.

US Patent:

7662931, Feb 16, 2010

Filed:

Aug 1, 2008

Appl. No.:

12/221418

Inventors:

Colin Gegg - Newbury Park CA, US
Fei Xiong - Thousand Oaks CA, US
Karen C. Sitney - Weston CT, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 16/00
A61K 38/00

US Classification:

5303917, 530350, 5303911

Abstract:

The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.